Number of shares and voting rights of ADOCIA as of November 30, 2021


LYON, France – (BUSINESS WIRE) – Regulatory news:

Pursuant to the provisions of article L. 233-8 II of the French Commercial Code and article 223-16 of the Stock Exchange Authority (Financial Markets Authority, or “AMF”) charter ADOCIA SA (Paris: ADOC), a French company anonimous society (company), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical stage biopharmaceutical company focused on the treatment of diabetes, obesity and metabolic diseases with innovative formulations of approved proteins, releases its total number of shares in circulation as well as its voting rights as of November 30e, 2021.



Total number of

outstanding shares

Total number of

theoretical vote

straight (1)

Total number of

exercisable vote

straight (2)





9 965 254

* including 86,780 new shares resulting from the conversion of 700,000 bonds convertible into shares (OC 1023) issued by the Company on October 26, 2021, the main characteristics of which are described in its press release of the same date.

(1) The total number of theoretical voting rights (or “gross” voting rights) is used as a basis for calculating the crossing of holding thresholds. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all the shares to which the voting right is attached, including the shares whose voting rights have been suspended.

(2) The total number of exercisable voting rights (or “net” voting rights) is calculated without taking into account the shares with suspended voting rights, in this case the shares held by the Company under a contract. liquidity.

About Adocia

Adocia is a clinical-stage biotechnology company specializing in the development of innovative formulations of therapeutic peptides and proteins for the treatment of diabetes and metabolic diseases. In diabetes, Adocia’s portfolio of injectable therapies is among the largest and most differentiated in the industry, with six clinical stage products and several preclinical products.

Adocia’s clinical pipeline includes five new formulations of insulin for the treatment of diabetes: two ultra-rapid formulations of insulin analog lispro (BioChaperone® Lispro U100 and U200), a combination of basal insulin glargine and rapid-acting insulin lispro (BioChaperone® Combo) and two combinations of a mealtime insulin with an amylin analogue pramlintide (M1Pram and BioChaperone® LisPram). The clinical pipeline also includes an aqueous formulation of human glucagon (BioChaperone® glucagon) for the treatment of hypoglycemia.

Adocia’s preclinical pipeline includes bihormonal combinations for the treatment of diabetes: a combination of fast-acting insulin analog aspart and pramlintide (BioChaperone® AsPram), a combination of insulin glargine with a GLP-1 receptor agonist (BioChaperone® Glargine Liraglutide). In addition, there are three multi-hormonal products for the treatment of obesity: a combination of glucagon and exenatide (BioChaperone® GluExe), a combination of pramlintide and exenatide (PramExe) and a triple combination of pramlintide glucagon exenatide (BioChaperone® PramGluExe).

Adocia’s portfolio is based on three technological platforms: 1) The BioChaperone® the platform is designed to improve the efficacy and / or safety of therapeutic proteins while making them easier to use for patients; 2) A platform designed to improve cell therapy techniques using a hydrogel matrix; 3) A platform for the oral administration of peptides.


This press release contains certain forward-looking statements regarding Adocia and its business. These forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in these forward-looking statements will be made, as these estimates are subject to numerous risks, including those set forth in the “Risk Factors” section of the Universal Registration Document. that was filed. with the Autorité des marchés financiers on April 20, 2021 (a copy of which is available at, in particular the uncertainties related to research and development, future clinical data, analyzes and the evolution of the economic context, the financial markets and the markets in which Adocia operates.

The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or considered not to be material by Adocia to date. The occurrence of some or all of these risks could cause the actual results, financial conditions, performance or achievements of Adocia to differ materially from those mentioned in forward-looking statements.

This press release and the information it contains do not constitute an offer to sell or the solicitation of an offer to buy Adocia shares in any jurisdiction.



Gerard Soula
Phone. : +33 4 72 610 610

MC Services SA

Adocia Press Relations Europe

Raimund Gabriel, Shaun Brown, Andreas Jungfer
Phone. : +49 89 210 228 0

Copyright © acrofan / Business Wire All rights reserved


Comments are closed.